Literature DB >> 24488981

Quantitative Doppler-echocardiographic imaging and clinical outcomes with left ventricular systolic dysfunction: independent effect of pulmonary hypertension.

Wayne L Miller1, Douglas W Mahoney, Maurice Enriquez-Sarano.   

Abstract

BACKGROUND: Doppler-echocardiography provides quantitative imaging of systolic and diastolic left ventricular (LV) function, functional mitral regurgitation (FMR), and pulmonary hypertension (PH) in patients with LV systolic dysfunction. Whether PH is linked to survival independently of LV features and FMR in symptomatic and asymptomatic patients is unknown. METHODS AND
RESULTS: Patients with LV ejection fraction ≤40% and quantitative Doppler-echocardiography assessment of FMR and PH were studied. Patients were frequency matched for those with Doppler-echocardiography estimated pulmonary systolic pressure ≥45 mm Hg (n=692) and those without PH (n=692; pulmonary systolic pressure, <45 mm Hg) for age, sex, LV ejection fraction, and quantified FMR severity and analyzed for long-term survival after diagnosis. During follow-up (median, 8.9 years), 885 deaths (63.5%) occurred, with PH being associated with higher 5-year mortality: 51±2% versus 37±2%, P<0.001. In multivariate analysis, PH demonstrated increased mortality risk independent of age, sex, severity of diastolic and systolic LV dysfunction, FMR, comorbidities, and symptom (hazard ratio, 1.34; 95% confidence limit, 1.17-1.53; P<0.001). Subgroup analysis, stratified by symptoms, degree of FMR, and severity of LV dysfunction, demonstrated that PH was associated with excess mortality in all subgroups.
CONCLUSIONS: In this large cohort of patients with LV systolic dysfunction, in whom FMR and LV characteristics were quantified and matched between those with and without PH, the presence of PH was an independent factor for excess mortality and not a surrogate for the severity of LV systolic dysfunction or FMR. In asymptomatic or symptomatic patients with or without FMR, PH is a critical marker for poor outcomes.

Entities:  

Keywords:  hypertension, pulmonary; outcomes; systolic dysfunction

Mesh:

Year:  2014        PMID: 24488981     DOI: 10.1161/CIRCIMAGING.113.001184

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  7 in total

Review 1.  Exercise echocardiography for structural heart disease.

Authors:  Masaki Izumo; Yoshihiro J Akashi
Journal:  J Echocardiogr       Date:  2016-01-13

Review 2.  Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV.

Authors:  Sriram D Rao; Jonathan N Menachem; Edo Y Birati; Jeremy A Mazurek
Journal:  Curr Heart Fail Rep       Date:  2019-10

3.  Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease.

Authors:  Orly Leiva; Siyang Ren; Donna Neuberg; Ankeet Bhatt; Andrew Jenkins; Rachel Rosovsky; Rebecca Karp Leaf; Katayoon Goodarzi; Gabriela Hobbs
Journal:  Int J Hematol       Date:  2022-10-02       Impact factor: 2.319

Review 4.  Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.

Authors:  Nicholas E King; Evan Brittain
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

5.  Pulmonary Hypertension in Aortic and Mitral Valve Disease.

Authors:  Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli
Journal:  Front Cardiovasc Med       Date:  2018-05-23

6.  Cardiac Manifestations in a Group of Romanian Patients with Gaucher Disease Type 1 (a Monocentric Study).

Authors:  Cecilia Lazea; Simona Bucerzan; Camelia Al-Khzouz; Anca Zimmermann; Ștefan Cristian Vesa; Ioana Nașcu; Victoria Creț; Mirela Crișan; Carmen Asăvoaie; Diana Miclea; Paula Grigorescu-Sido
Journal:  Diagnostics (Basel)       Date:  2021-05-29

7.  Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire.

Authors:  Razvan Capota; Sebastian Militaru; Alin Alexandru Ionescu; Monica Rosca; Cristian Baicus; Bogdan Alexandru Popescu; Ruxandra Jurcut
Journal:  Health Qual Life Outcomes       Date:  2020-10-30       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.